Details for New Drug Application (NDA): 206177
✉ Email this page to a colleague
NDA 206177 describes DOCETAXEL, which is a drug marketed by Accord Hlthcare, Acic Pharms, Actavis, Alembic, Amneal, Apotex Inc, Dfb Oncology Ltd, Dr Reddys, Eugia Pharma, Gland Pharma Ltd, Hengrui Pharma, Hikma, Hospira Inc, Meitheal, Mylan Labs Ltd, Norvium Bioscience, Novast Labs, Pfizer Labs, Sandoz, Shilpa, Sun Pharm, and Teva Pharms Usa, and is included in twenty-seven NDAs. It is available from twenty suppliers. There are four patents protecting this drug. Additional details are available on the DOCETAXEL profile page.
The generic ingredient in DOCETAXEL is docetaxel. There are forty-one drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the docetaxel profile page.
The generic ingredient in DOCETAXEL is docetaxel. There are forty-one drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the docetaxel profile page.
Summary for 206177
| Tradename: | DOCETAXEL |
| Applicant: | Dfb Oncology Ltd |
| Ingredient: | docetaxel |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 20MG/ML (20MG/ML) | ||||
| Approval Date: | Jan 20, 2017 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 80MG/4ML (20MG/ML) | ||||
| Approval Date: | Jan 20, 2017 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 200MG/10ML (20MG/ML) | ||||
| Approval Date: | Jan 20, 2017 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
